August 2012
-
Johnson & Johnson subsidiary Cilag GmbH International will pay a total of $330 million to AstraZeneca for rights to Rhinocort Aqua budesonide nasal spray outside of the US, AstraZeneca has announced. Cilag operates as part… Read more . . .
-
Aradigm Corporation has partnered with Professors Daniela Traini and Paul Young of the University of Sydney’s Woolcock Institute of Medical Research to develop an aerosol nanoparticle technology to combat fungal and bacterial biofilms. The project… Read more . . .
-
The Intelligent Control Inhaler from 3M Drug Delivery Systems has won the drug delivery devices category of the CPhI Pharma Awards. According to CPhI, the inhaler was recognized “for its approach to addressing patient adherence… Read more . . .
-
French device company Biocorp has announced the launch of its Inspair sensor, which it says is “capable of converting any pressurized metered dose inhaler into a connected device.” According to the company, the sensor works… Read more . . .
-
Chiesi Farmaceutici has submitted an MAA to the European Medicines Agency (EMA) for its extra-fine ICS/LABA/LAMA combination inhaler for the treatment of COPD. The submission is the first for a triple combination inhaler. In June… Read more . . .
-
Health Canada has approved Adapt Pharma’s Narcan naloxone nasal spray for reversal of known or suspected opioid overdose. The approval comes three months after Health Canada announced that it would allow importation of Narcan nasal… Read more . . .
-
OptiNose has appointed Tom Gibbs as Chief Commercial Officer to oversee the commercialization strategy for EDS-FLU (OPN-375) intranasal fluticasone, which is in Phase 3 development for the treatment of nasal congestion in patients with nasal… Read more . . .
-
Insmed has appointed Roger Adsett, a former global brand director for Symbicort, as its new Chief Commercial Officer in preparation for commercialization of Arikayce inhaled liposomal amikacin. Adsett also spent a portion of his time… Read more . . .
-
Mast Therapeutics has announced that it will stop its development program for vepoloxamer and will devote its resources to development of AIR001 sodium nitrite inhalation solution for patients with heart failure with preserved ejection fraction… Read more . . .
-
California-based simulation and modeling software company Simulations Plus has announced that it will join the SimInhale COST (European Cooperation in Science and Technology) Action consortium, which aims to “advance particle designs for improved deposition and… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland